Shanghai Pharma To List In HK; Pfizer Possible Investor
This article was originally published in PharmAsia News
Shanghai Pharmaceutical will be listed on the Hong Kong and H share stock markets May 6
You may also be interested in...
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.
Medtronic has agreed to licensing and development agreements with cash-strapped surgical robotics company Titan receiving payments up to $31m pending certain milestones.
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.